Business Context and Reporting Period
Corbus Pharmaceuticals Holdings, Inc., an emerging growth company, filed this Form 8-K on January 5, 2018. The report details the entry into a material definitive agreement to facilitate the sale of common stock.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the authorization of a potential equity offering.
Material Changes
On January 5, 2018, the Company entered into a Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. as the sales agent. Under this agreement, the Company may offer and sell shares of its common stock with an aggregate offering price of up to $50.0 million. The Company is not obligated to sell any shares under this agreement.
Guidance, Outlook, and Risks
- Offering Structure: Shares may be sold through "at the market" offerings based on the Company's instructions regarding price, time, and size limits.
- Compensation: The Company will pay Cantor Fitzgerald a commission of 3.0% of the aggregate gross proceeds from each sale.
- Conditions: The sales agent's obligations are subject to the effectiveness of the Registration Statement on Form S-3 filed on January 5, 2018, and other customary closing conditions.
- Expenses: The Company has agreed to reimburse Cantor Fitzgerald for certain specified expenses.
Investor Verification Checklist
- Verify the effectiveness status of the Form S-3 Registration Statement filed on January 5, 2018.
- Monitor future filings for actual share sales executed under the Sales Agreement.
- Review the full text of the Sales Agreement (Exhibit 1.1) for specific terms regarding indemnification and contribution rights.
- Confirm the Company's current cash position to assess the necessity of the potential $50.0 million capital raise.